Open AccessMicroRNA-26a-5p as a potential predictive factor for determining the effectiveness of trastuzumab therapy in HER-2 positive breast cancer patients
Author(s) -
Sadra Samavarchi Tehrani,
Ehsan Zaboli,
Farzin Sadeghi,
Soraya Khafri,
Ansar Karimian,
Mahnoosh Rafie,
Hadi Parsian
Publication year - 2021
Publication title -
biomedicine
Language(s) - English
Resource type - Journals
eISSN - 2211-8039
pISSN - 2211-8020
DOI - 10.37796/2211-8039.1150
Subject(s) - trastuzumab , medicine , docetaxel , breast cancer , microrna , oncology , estrogen receptor , pathological , cancer , chemotherapy , gene , biology , biochemistry
Breast cancer (BC) is known as the most prevalent type of cancer among women. Trastuzumab, as an anticancer drug, has been used broadly in human epidermal growth factor receptor 2 (HER-2) positive (+) BC patients. Moreover, accumulating evidence has demonstrated that microRNAs is involved in the pathogenesis BC. Hence, we aimed to investigate the effect of trastuzumab on the expression levels of microRNA-26a in HER-2 positive BC patients.